|
Name |
Santene
|
Molecular Formula | C9H14 | |
IUPAC Name* |
2,3-dimethylbicyclo[2.2.1]hept-2-ene
|
|
SMILES |
CC1=C(C2CCC1C2)C
|
|
InChI |
InChI=1S/C9H14/c1-6-7(2)9-4-3-8(6)5-9/h8-9H,3-5H2,1-2H3
|
|
InChIKey |
LSIXBBPOJBJQHN-UHFFFAOYSA-N
|
|
Synonyms |
SANTENE; Santen; 2,3-Dimethylbicyclo[2.2.1]hept-2-ene; 529-16-8; 2-Norbornene, 2,3-dimethyl-; 2,3-dimethyl-2-norbornene; 2,3-Dimethylbicyclo(2.2.1)hept-2-ene; 2,3-Dimethyl-Bicyclo(2.2.1)hept-2-ene; 2,3-dimethyl-bicyclo[2.2.1]hept-2-ene; Bicyclo(2.2.1)hept-2-ene, 2,3-dimethyl-; Bicyclo[2.2.1]hept-2-ene, 2,3-dimethyl-; dimethylnorbornene; DTXSID20870585; CHEBI:184421; ALBB-035088; SANTENE;2,3-dimethyl-2-Norbornene; 2,3-dimethylbicyclo[2.2.1]-2-heptene; 2,3-dimethylbicyclo[2.2.1]-hept-2-ene; 2,3-Dimethylbicyclo[2.2.1]hept-2-ene #
|
|
CAS | 529-16-8 | |
PubChem CID | 10720 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 122.21 | ALogp: | 2.2 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 9 | QED Weighted: | 0.431 |
Caco-2 Permeability: | -4.403 | MDCK Permeability: | 0.00002680 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.147 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.01 |
Blood-Brain-Barrier Penetration (BBB): | 0.948 | Plasma Protein Binding (PPB): | 96.03% |
Volume Distribution (VD): | 3.648 | Fu: | 2.71% |
CYP1A2-inhibitor: | 0.558 | CYP1A2-substrate: | 0.914 |
CYP2C19-inhibitor: | 0.216 | CYP2C19-substrate: | 0.901 |
CYP2C9-inhibitor: | 0.166 | CYP2C9-substrate: | 0.869 |
CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.904 |
CYP3A4-inhibitor: | 0.169 | CYP3A4-substrate: | 0.4 |
Clearance (CL): | 16.857 | Half-life (T1/2): | 0.205 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.254 |
Drug-inuced Liver Injury (DILI): | 0.071 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.035 | Maximum Recommended Daily Dose: | 0.089 |
Skin Sensitization: | 0.32 | Carcinogencity: | 0.334 |
Eye Corrosion: | 0.9 | Eye Irritation: | 0.977 |
Respiratory Toxicity: | 0.764 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000151 | 0.333 | D04CSZ | 0.227 | ||||
ENC000791 | 0.256 | D0V8HA | 0.213 | ||||
ENC001331 | 0.250 | D07GRH | 0.196 | ||||
ENC002374 | 0.245 | D0LM4A | 0.177 | ||||
ENC000808 | 0.245 | D0H1QY | 0.174 | ||||
ENC001346 | 0.239 | D0A2AJ | 0.172 | ||||
ENC000482 | 0.238 | D0WO8W | 0.172 | ||||
ENC000613 | 0.238 | D03DVJ | 0.167 | ||||
ENC001887 | 0.237 | D07QKN | 0.163 | ||||
ENC000950 | 0.227 | D09RHQ | 0.157 |